Henry Rinder, MD
Professor of Laboratory Medicine and of Medicine (Hematology)Cards
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Vice Chair for Clinical Affairs, Laboratory Medicine
Associate Director, Yale Pathology Residency Program
Director, Clinical Hematology Laboratory
Contact Info
Laboratory Medicine
PO Box 208035
New Haven, CT 06520-8035
United States
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Vice Chair for Clinical Affairs, Laboratory Medicine
Associate Director, Yale Pathology Residency Program
Director, Clinical Hematology Laboratory
Contact Info
Laboratory Medicine
PO Box 208035
New Haven, CT 06520-8035
United States
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Vice Chair for Clinical Affairs, Laboratory Medicine
Associate Director, Yale Pathology Residency Program
Director, Clinical Hematology Laboratory
Contact Info
Laboratory Medicine
PO Box 208035
New Haven, CT 06520-8035
United States
About
Titles
Professor of Laboratory Medicine and of Medicine (Hematology)
Vice Chair for Clinical Affairs, Laboratory Medicine; Associate Director, Yale Pathology Residency Program; Director, Clinical Hematology Laboratory
Biography
My academic background is in hematology. After training in internal medicine and hematology, I went on to post-doctoral work in clinical pathology to bolster our clinical and research activities.
Our laboratory research focuses on cell-based diagnostics relevant to the basic biology of hemostasis and inflammation. We have evaluated the role of thrombin and complement in platelet dysfunction following extracorporeal circulation, studies of metabolic changes during platelet storage, hypercoagulability in drug abuse, and platelet function under the control of growth factors.
We also seek to understand platelet kinetics in a variety of disorders using the non-invasive peripheral blood assay for reticulated platelets. Our collaborative focus on research additionally includes: murine disease models of platelet activation and kinetics; cell-based vascular risk associated with CPB; platelet physiology; and neutrophil markers for early recognition of sepsis.
These rewarding areas of investigation have seamlessly led to clinical investigation and educative endeavors, including becoming an author on the 4th and 5th editions of Hillman's Hematology in Clinical Practice (McGraw-Hill) and serving currently on the Board of Directors of the American Society for Clinical Pathology (ASCP) and as the chair of the ASCP Commission on Continuing Professional Development.
Appointments
Laboratory Medicine
ProfessorPrimary
Other Departments & Organizations
- Apheresis
- Clinical Hematology Laboratory
- General Hematology
- Laboratory Medicine
- Laboratory Medicine - Education
- Training in Lab Med and Pathology
- Yale Medicine
- Yale Ventures
Education & Training
- Fellow
- Yale University School of Medicine (1992)
- Fellow
- Yale University School of Medicine (1990)
- Chief Resident
- Maine Medical Center (1988)
- Resident
- Maine Medical Center (1987)
- MD
- University of Vermont (1984)
Research
Overview
Medical Research Interests
ORCID
0000-0001-7271-7447
Research at a Glance
Yale Co-Authors
Publications Timeline
Research Interests
Brian Richard Smith, MD
Alexa Siddon, MD
Christopher Tormey, MD
Alfred Lee, MD, PhD
Ayesha Butt, MBBS
Sean Gu, MD/PhD
Blood Platelets
Cardiopulmonary Bypass
Blood Transfusion
Inflammation
Publications
2024
Overall survival in TP53-mutated AML and MDS
Puzo C, Hager K, Rinder H, Weinberg O, Siddon A. Overall survival in TP53-mutated AML and MDS. Annals Of Hematology 2024, 1-11. PMID: 39443370, DOI: 10.1007/s00277-024-06054-7.Peer-Reviewed Original ResearchConceptsOverall survivalBlast countTP53 mutationsSignificant predictors of OSP53 mutation typePredictors of OSAggressive disease biologyRetrospective chart reviewKaplan-Meier curvesYale-New Haven HospitalNext generation sequencingCox proportional hazards modelsProportional hazards modelComplex karyotypePoor OSP53 mutationsWHO criteriaChart reviewNew Haven HospitalPoor prognosisCo-mutationsPathogenic mutationsAMLICCS guidelinesMutation typeOptimization criteria for ordering myeloid neoplasm next‐generation sequencing
Gisriel S, Howe J, Tormey C, Torres R, Hager K, Rinder H, Siddon A. Optimization criteria for ordering myeloid neoplasm next‐generation sequencing. EJHaem 2024 DOI: 10.1002/jha2.1036.Peer-Reviewed Original ResearchConceptsNext-generation sequencingNext-generation sequencing testMyeloid neoplasmsDiagnosis of chronic myeloid leukemiaAltering treatment plansEnd-of-inductionFluorescence in situ hybridizationRecurrence post-transplantChronic myeloid leukemiaSuspicion of progressionPathogenic mutationsClinical suspicionMutation statusMN diagnosisMyeloid leukemiaPost-transplantRisk stratificationWorsening diseaseTreatment planningCancellation criteriaSuspicionDiagnosisSequenceCenters for MedicareB testAssessing the Effect of Changing the Average Hematocrit in Red Blood Cell (RBC) Units on the Post- Procedure Hematocrits of Patients Undergoing Erythrocytapheresis
Musante K, Roome L, Yurtsever N, Rinder H, Tormey C, Lee E. Assessing the Effect of Changing the Average Hematocrit in Red Blood Cell (RBC) Units on the Post- Procedure Hematocrits of Patients Undergoing Erythrocytapheresis. American Journal Of Clinical Pathology 2024, 162: s147-s147. DOI: 10.1093/ajcp/aqae129.326.Peer-Reviewed Original ResearchConceptsSickle cell diseaseRed blood cell unitsSickle cell disease patientsRed blood cellsPatient's HctRBC unitsTransfused RBC unitsRetrospective chart reviewTwo-sample t-testChart reviewAdverse eventsMedian numberPre-procedureProphylactic procedureCell diseasePatientsAcademic hospitalAverage hematocritAverage HctBlood cellsHctTransfusion servicesT-testQuality studiesHematocritHematocrits of red blood cell units increase during storage due to changes in mean corpuscular volume, impacting outcomes of red cell exchange procedures
Lee E, Musante K, Errico J, Rinder H, Kleinstein S, Tormey C, Yurtsever N. Hematocrits of red blood cell units increase during storage due to changes in mean corpuscular volume, impacting outcomes of red cell exchange procedures. American Journal Of Clinical Pathology 2024, 162: s157-s157. DOI: 10.1093/ajcp/aqae129.348.Peer-Reviewed Original ResearchConceptsMean corpuscular volumeMultilevel linear regression modelsPosterior meanStorage timeWeeks of storageRed blood cell exchangeFunction of storage timeLinear regression modelsRed blood cell unitsPosterior distribution of model parametersAkaike weightsMultilevel regression modelsRegression modelsRed blood cellsPosterior distributionDistribution of model parametersRBC unitsModel selectionRStan packageCorpuscular volumeHematological parametersFlow cytometry for RBC damage and complement activation
Villalba C, Yurtsever N, Paternoster K, Gallipoli P, Nash B, Bizzario L, Shah B, Rinder H, Tormey C, Lee E. Flow cytometry for RBC damage and complement activation. American Journal Of Clinical Pathology 2024, 162: s182-s183. DOI: 10.1093/ajcp/aqae129.400.Peer-Reviewed Original ResearchConceptsDirect antiglobulin testRed blood cellsTukey HSD testHSD testAntiglobulin testComplement depositionOne-way ANOVANegative direct antiglobulin testFlow cytometryRed blood cell clearanceStatistically significant differenceTwo-sample t-testPercentage of red blood cellsExposure of PSHealthy donorsDiluted red blood cellsRBC recoveryRBC unitsPhosphatidylserine expressionRBC injuryFlow cytometry assayHealthy individualsPS expressionRed blood cell ageComplement activationPhenotypic and genotypic evaluation of bleeding diagnostic dilemmas: Two case studies
Gu S, Butt A, Schulz V, Rinder H, Lee A, Gallagher P, Hwa J, Bona R. Phenotypic and genotypic evaluation of bleeding diagnostic dilemmas: Two case studies. Blood Cells Molecules And Diseases 2024, 110: 102893. PMID: 39260211, DOI: 10.1016/j.bcmd.2024.102893.Peer-Reviewed Original ResearchConceptsInherited platelet disordersClinically significant bleedingCases of patientsHeterogeneous group of conditionsGroup of conditionsSignificant bleedingDiagnostic yieldDiagnostic dilemmaPlatelet disordersBleeding disordersEvaluating patientsPatient cohortMolecular pathogenesisMass cytometryHeterogeneous groupPatientsMultimodal approachBleedingImprove patient careDiagnosisDisordersPatient careGenetic sequencesLaboratory testing approachPotential utilityThrombosis risk with haemoglobin C trait and haemoglobin C disease: A systematic review
Jacobs J, Sharma D, Stephens L, Villalba C, Rinder H, Woo J, Wheeler A, Gerberi D, Goel R, Tormey C, Booth G, Bloch E, Adkins B. Thrombosis risk with haemoglobin C trait and haemoglobin C disease: A systematic review. British Journal Of Haematology 2024, 204: 1500-1506. PMID: 38291731, DOI: 10.1111/bjh.19313.Peer-Reviewed Original ResearchAltmetricConceptsRisk of thrombosisHemoglobin C traitHemoglobin C diseaseVenous thromboembolismC diseaseIncreased risk of thrombosisProspective cohort studyFactor to thrombosisAssessment of patientsCohort studySystematic reviewInclusion criteriaPregnant individualsThrombotic riskCase seriesCase reportVTE riskChronic haemolysisSystematic literature reviewArterial thrombosisThrombosis riskHigh blood viscosityIncreased riskThrombosisC trait
2023
Heidenhain variant of Creutzfeldt-Jakob disease masquerading as neuromyelitis optica spectrum disorder: recognizing when apheresis is not the answer
Burke O, Jacobs J, Tormey C, Rinder H, Villalba C, Lee E, Campos J, Abels E, Yurtsever N. Heidenhain variant of Creutzfeldt-Jakob disease masquerading as neuromyelitis optica spectrum disorder: recognizing when apheresis is not the answer. Lab Medicine 2023, 55: 520-523. PMID: 38142129, DOI: 10.1093/labmed/lmad107.Peer-Reviewed Original ResearchConceptsNeuromyelitis optica spectrum disorderCreutzfeld-Jakob diseaseOptica spectrum disorderHeidenhain variantBilateral vision lossTherapeutic plasma exchangeReal-time quaking-induced conversionCreutzfeldt-Jakob diseaseImmunosuppressive therapyVisual disturbancesPlasma exchangeNeurocognitive symptomsTreatment modalitiesVision lossHospice careSpectrum disorderRare formPreliminary diagnosisDiseaseDiagnosisDisordersEarly stagesPatientsApheresisTherapyComprehensive Characterization of Coagulation Parameters in Venous Malformations
Restrepo V, Pine A, Butt A, Chang E, Bar N, Baluha A, Brooks A, Chirico G, Curran J, Dumont A, Obura-Wilkes P, Rinder H, Tormey C, Nassiri N, Lee A, Prozora S. Comprehensive Characterization of Coagulation Parameters in Venous Malformations. Blood 2023, 142: 27. DOI: 10.1182/blood-2023-190609.Peer-Reviewed Original ResearchConceptsHigher thrombin-antithrombin complexesNormal D-dimerThrombin-antithrombin complexPlasminogen activator inhibitor-1Localized intravascular coagulopathyInternational normalized ratioD-dimerVenous malformationsCoagulation parametersPartial thromboplastin timeCoagulation testsFactor VIIIVWF activityChart reviewMost patientsHematology clinicProthrombin timeTissue involvementVWF antigenVon Willebrand factor antigenHigher TAT levelsMultiple coagulation parametersBaseline patient characteristicsRetrospective chart reviewCoagulation test resultsMultimodality Platelet Evaluation By Mass Cytometry and Genetic Analysis in Patients with Bleeding Disorders
Gu S, Gallagher P, Butt A, Gu V, Lezon-Geyda K, Schulz V, Prozora S, Lee A, Neparidze N, Bar N, Martin K, Cornell J, Chirico G, Chakraborty R, Rinder H, Hwa J, Bona R. Multimodality Platelet Evaluation By Mass Cytometry and Genetic Analysis in Patients with Bleeding Disorders. Blood 2023, 142: 1197. DOI: 10.1182/blood-2023-177946.Peer-Reviewed Original ResearchConceptsBleeding tendencyBleeding disorderPlatelet markersPlatelet aggregometryMass cytometryPlatelet functionPlatelet disordersSingle-center prospective studyLow-risk groupAbnormal bleeding tendencyQualitative platelet disordersLarge patient cohortQuantitative platelet disordersCommon underlying causeGenetic variantsMultimodality evaluationTotal patientsRisk stratificationLaboratory suspicionPlatelet dysfunctionProspective studyPatient cohortUnivariate analysisPlatelet volumeRisk groups
Academic Achievements & Community Involvement
honor Past President
International AwardAcademy of Clinical Laboratory Physicians & ScientistsDetails05/29/2016United Stateshonor Michele D. Raible Lecturer
International AwardAmerican Society for Clinical PathologyDetails09/30/2015United Stateshonor 2013 President's Award
International AwardAmerican Society for Clinical PathologyDetails09/30/2013United States
Clinical Care
Overview
Henry Rinder, MD, is a hematologist, helping bolster research and clinical care surrounding various blood disorders, including bleeding and clotting diseases, anemias, and blood complications from other diseases.
Dr. Rinder's research focuses on cell-based diagnostics and basic biology principles involving inflammation and hemostasis—the body's reaction to an injury; this reaction stops the bleeding and allows the body to begin healing.
Through his clinical and research work, Dr. Rinder has established himself as an authority in hematology, including becoming an author on the 4th and 5th editions of Hillman's Hematology in Clinical Practice (McGraw-Hill).
Dr. Rinder is a professor of laboratory medicine and internal medicine (hematology) at Yale School of Medicine.
Clinical Specialties
Board Certifications
Clinical Pathology
- Certification Organization
- AB of Pathology
- Latest Certification Date
- 2014
- Original Certification Date
- 1994
Internal Medicine
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 1987
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileNews
News
- September 05, 2024
Henry Rinder, MD, Receives 2024 ASCP Mastership Award
- February 06, 2024
The FDA’s Proposed Ruling on Lab Tests Could Have Unintended Consequences
- August 11, 2022
Discoveries & Impact (August 2022)
- May 11, 2022
Andrea Barbieri, MD, to Succeed Diane Kowalski, MD, MMSc, as Director of Pathology Residency Training Program
Get In Touch
Contacts
Laboratory Medicine
PO Box 208035
New Haven, CT 06520-8035
United States
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.